New York Approves BioTheranostics to Offer Breast Cancer MDx | GenomeWeb

NEW YORK (GenomeWeb) – The New York State Department of Health has approved BioTheranostics to offer its Breast Cancer Index to residents in the state, the company said today.

The molecular diagnostic test quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer. According to the San Diego firm, it is the only commercially available biomarker for estrogen receptor-positive breast cancer patients that accurately predicts early and late distant recurrence of the disease while also predicting the benefit from extended endocrine therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.